P53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis

Biochemical and Biophysical Research Communications

Volumn 416, Issue 1-2, 2011, Pages 222-225

  Seol, Dai Wu ^a,b  

^a Chung Ang University   (South Korea)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; DR5; Glioma; P53; Proteasome inhibitor; TRAIL; Velcade

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; DACTINOMYCIN; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; LACTACYSTIN; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG POTENTIATION; GLIOMA; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; GLIOMA; HUMANS; LEUPEPTINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 83055179401     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.11.053     Document Type: Article

References (18)

1. Maher E.A., Furnari F.B., Bachoo R.M., et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15:1311-1333.
2. Lefranc F., Brotchi J., Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 2005, 23:2411-2422.
3. Wiley S.R., Schooley K., Smolak PJ P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
4. Pitti R.M., Marsters S.A., Ruppert S S. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
5. Ashkenazi A., Pai R.C., Fong S. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
6. Walczak H., Miller R.E., Ariail K. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
7. MacFarlane M., Ahmad M., Srinivasula S.M. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 1997, 272:25417-25420.
8. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
9. Kim P.K., Mahidhara R., Seol D.W. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist. Updat. 2001, 5:293-296.
10. Enari M., Sakahira H., Yokoyama H., et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
11. Sakahira H., Enari M., Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998, 391:96-99.
12. Liu X., Li P., Widlak P., et al. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95:8461-8466.
13. Held J., Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist. Updat. 2001, 4:243-252.
14. Wajant H., Pfizenmaier K., Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7:449-459.
15. Seol D.W., Li J., Seol M.H., et al. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res. 2001, 61:1138-1143.
16. Kim M., Park S.Y., Pai H.S., et al. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res. 2004, 64:4078-4081.
17. Takimoto R., El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743.
18. Van Meir E.G., Kikuchi T., Tada M M. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 1994, 54:649-652.